ShangPharma appoints chief biologics officer
This article was originally published in Scrip
Contract research organization, ShangPharma has named Dr Mitchell Reff chief biologics officer, effective from 13 January 2014. Prior to joining the Shanghai, China-based firm Dr Reff held a number of positions at Biogen Idec during a 21-year career with the firm, including vice-president of discovery oncology. At ShangPharma he will join the ChemPartner's Biologics Division, which offers pharmaceutical and biotechnology companies strategic and technical expertise to discover and manufacture novel biologics.
You may also be interested in...
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care.